Somalogic Operating Co., INC.
SomaLogic is a protein biomarker discovery and clinical diagnostics company.
Based in CO
🤖
AI Overview
With $706K in lobbying spend across 18 quarterly filings, Somalogic Operating Co., INC is an active lobbying client. Their lobbying covers 8 issue areas. Active from 2021 to 2025.
$706K
Total Spend
5
Years Active
1
Firms Hired
1
Lobbyists Deployed
8
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $11K |
| 2022 | $196K |
| 2023 | $211K |
| 2024 | $144K |
| 2025 | $144K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Defense, Veterans, Medicare/Medicaid, Budget/Appropriations, Pharmacy and 3 more
- •Working with appropriate government agencies and entities to explore areas of funding, procurement, regulatory issues and scientific/medical development and deployment. Tracking legislation and workin
Related Analysis
📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Defense Lobbying
Industry overview and top spenders
🏭 Pharma Lobbying
Industry overview and top spenders
🏭 Tech Lobbying
Industry overview and top spenders
Related Investigations
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Lobbying vs. Federal Contracts
How lobbying spending correlates with contract awards.
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.